title: PMC, a potent hydrophilic α-tocopherol derivative, inhibits NF-κB activation via PP2A but not IκBα-dependent signals in vascular smooth muscle cells.
abstract: The hydrophilic α-tocopherol derivative, 2,2,5,7,8-pentamethyl-6-hydroxychromane (PMC), is a promising alternative to vitamin E in clinical applications. Critical vascular inflammation leads to vascular dysfunction and vascular diseases, including atherosclerosis, hypertension and abdominal aortic aneurysms. In this study, we investigated the mechanisms of the inhibitory effects of PMC in vascular smooth muscle cells (VSMCs) exposed to pro-inflammatory stimuli, lipopolysaccharide (LPS) combined with interferon (IFN)-γ. Treatment of LPS/IFN-γ-stimulated VSMCs with PMC suppressed the expression of inducible nitric oxide synthase (iNOS) and matrix metalloproteinase-9 in a concentration-dependent manner. A reduction in LPS/IFN-γ-induced nuclear factor (NF)-κB activation was also observed in PMC-treated VSMCs. The translocation and phosphorylation of p65, protein phosphatase 2A (PP2A) inactivation and the formation of reactive oxygen species (ROS) were significantly inhibited by PMC in LPS/IFN-γ-activated VSMCs. However, neither IκBα degradation nor IκB kinase (IKK) or ribosomal s6 kinase-1 phosphorylation was affected by PMC under these conditions. Both treatments with okadaic acid, a PP2A-selective inhibitor, and transfection with PP2A siRNA markedly reversed the PMC-mediated inhibition of iNOS expression, NF-κB-promoter activity and p65 phosphorylation. Immunoprecipitation analysis of the cellular extracts of LPS/IFN-γ-stimulated VSMCs revealed that p65 colocalizes with PP2A. In addition, p65 phosphorylation and PP2A inactivation were induced in VSMCs by treatment with H(2)O(2), but neither IκBα degradation nor IKK phosphorylation was observed. These results collectively indicate that the PMC-mediated inhibition of NF-κB activity in LPS/IFN-γ-stimulated VSMCs occurs through the ROS-PP2A-p65 signalling cascade, an IKK-IκBα-independent mechanism. Therapeutic interventions using PMC may therefore be beneficial for the treatment of vascular inflammatory diseases.
authors.affiliation: Department of Pharmacology, School of Medicine, Taipei Medical University, Taipei, Taiwan.
authors.forename: Cheng-Ying
authors.initials: CY
authors.lastname: Hsieh
authors.forename: George
authors.initials: G
authors.lastname: Hsiao
authors.forename: Ming-Jen
authors.initials: MJ
authors.lastname: Hsu
authors.forename: Yi-Hsuan
authors.initials: YH
authors.lastname: Wang
authors.forename: Joen-Rong
authors.initials: JR
authors.lastname: Sheu
mesh_terms: D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology*; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D005455:Fluorescent Antibody Technique; D006861:Hydrogen Peroxide / Q000494:pharmacology; D051550:I-kappa B Kinase / Q000378:metabolism; D020672:I-kappa B Proteins / Q000378:metabolism*; D047468:Immunoprecipitation; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D018613:Microscopy, Confocal; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism*; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D016877:Oxidants / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D054648:Protein Phosphatase 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: C554178:2,2,5,7,8-pentamethyl-6-hydroxychromane; D001578:Benzopyrans; D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D016328:NF-kappa B; C000606206:Nfkbia protein, rat; D016877:Oxidants; D034741:RNA, Small Interfering; D017382:Reactive Oxygen Species; D000072000:NF-KappaB Inhibitor alpha; D009569:Nitric Oxide; D007371:Interferon-gamma; D006861:Hydrogen Peroxide; D052247:Nitric Oxide Synthase Type II; D051550:I-kappa B Kinase; D054648:Protein Phosphatase 2
keywords: NF-κB; PMC; PP2A; ROS; vascular inflammation
references.citation: Br J Haematol. 2002 Jun;117(3):699-704
references.pmid: 12028044
references.citation: Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):472-9
references.pmid: 19201691
references.citation: J Clin Invest. 2002 Aug;110(4):463-74
references.pmid: 12189240
references.citation: Cell Res. 2011 Jan;21(1):103-15
references.pmid: 21187859
references.citation: Methods Cell Biol. 1997;52:133-54
references.pmid: 9379948
references.citation: Biochem Pharmacol. 2007 Mar 1;73(5):682-93
references.pmid: 17157267
references.citation: Nat Rev Immunol. 2002 Oct;2(10):725-34
references.pmid: 12360211
references.citation: BioDrugs. 2006;20(5):271-3
references.pmid: 17025373
references.citation: Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62
references.pmid: 17183360
references.citation: Chem Res Toxicol. 2005 Oct;18(10):1567-74
references.pmid: 16533021
references.citation: Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1213-9
references.pmid: 19443843
references.citation: BMJ. 2013 Jan 18;346:f10
references.pmid: 23335472
references.citation: J Biol Chem. 2004 Jun 18;279(25):26115-25
references.pmid: 15073170
references.citation: Science. 1992 Aug 28;257(5074):1261-4
references.pmid: 1325671
references.citation: J Biol Chem. 2011 Feb 25;286(8):5942-55
references.pmid: 21169355
references.citation: Biochem Pharmacol. 2003 Apr 15;65(8):1383-92
references.pmid: 12694879
references.citation: Int J Biochem Cell Biol. 2009 Jun;41(6):1284-95
references.pmid: 19038359
references.citation: J Biol Chem. 2001 Dec 21;276(51):47828-33
references.pmid: 11591705
references.citation: Cardiovasc Res. 2004 Jul 1;63(1):31-40
references.pmid: 15194459
references.citation: FASEB J. 2002 Dec;16(14):1931-3
references.pmid: 12368228
references.citation: Mol Aspects Med. 2007 Oct-Dec;28(5-6):423-36
references.pmid: 17320165
references.citation: Eur J Nutr. 2012 Oct;51(7):769-81
references.pmid: 22684632
references.citation: Cardiovasc Res. 2009 Dec 1;84(3):494-504
references.pmid: 19617223
references.citation: Antioxid Redox Signal. 2013 Dec 10;19(17):2157-96
references.pmid: 23458328
references.citation: J Biol Chem. 2003 Sep 19;278(38):36973-9
references.pmid: 12860993
references.citation: Nat Clin Pract Cardiovasc Med. 2007 Aug;4(8):444-54
references.pmid: 17653117
references.citation: Cell. 2000 Jan 7;100(1):113-27
references.pmid: 10647936
references.citation: Free Radic Biol Med. 2011 Sep 1;51(5):978-92
references.pmid: 21627987
references.citation: Cell. 2009 Oct 30;139(3):468-84
references.pmid: 19879837
references.citation: Cardiovasc Res. 2003 Apr 1;58(1):186-95
references.pmid: 12667961
references.citation: Cell. 2002 Apr;109 Suppl:S81-96
references.pmid: 11983155
references.citation: Mol Cell. 2006 Nov 17;24(4):497-509
references.pmid: 17188031
references.citation: Cell. 2007 Jul 13;130(1):21-4
references.pmid: 17632053
references.citation: Free Radic Biol Med. 2010 Sep 1;49(5):881-93
references.pmid: 20600839
references.citation: Ann Intern Med. 2005 Jan 4;142(1):37-46
references.pmid: 15537682
references.citation: Haematologica. 2013 May;98(5):793-801
references.pmid: 23065519
references.citation: Nat Rev Cardiol. 2009 Jun;6(6):410-7
references.pmid: 19421244
references.citation: Mol Biol Cell. 2007 Dec;18(12):4691-7
references.pmid: 17898080
references.citation: J Clin Invest. 1991 Feb;87(2):602-8
references.pmid: 1671393